Q32 Bio
QTTB
39 hedge funds and large institutions have $126M invested in Q32 Bio in 2024 Q1 according to their latest regulatory filings, with 13 funds opening new positions, 5 increasing their positions, 14 reducing their positions, and 30 closing their positions.
1,000% more capital invested
Capital invested by funds: $11.4M → $126M (+$114M)
228.24% more ownership
Funds ownership: 1.8% → 230.04% (+228%)
32% less funds holding
Funds holding: 57 → 39 (-18)
57% less first-time investments, than exits
New positions opened: 13 | Existing positions closed: 30
64% less repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 14
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
+$31M |
| 2 |
AVLSA
Atlas Venture Life Science Advisors
Cambridge,
Massachusetts
|
+$28.8M |
| 3 |
CG
Carlyle Group
Washington,
District of Columbia
|
+$15.2M |
| 4 |
VC
Vivo Capital
Palo Alto,
California
|
+$4.82M |
| 5 |
AVM
Arch Venture Management
Chicago,
Illinois
|
+$4.42M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NM
Newtyn Management
New York
|
-$851K |
| 2 |
BCM
BML Capital Management
Zionsville,
Indiana
|
-$230K |
| 3 |
BlackRock
New York
|
-$220K |
| 4 |
GKFF
George Kaiser Family Foundation
Tulsa,
Oklahoma
|
-$186K |
| 5 |
Renaissance Technologies
New York
|
-$106K |
QTTB Hedge Fund Activity: Q1 2024 in Review
39 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in Q32 Bio (QTTB) for Q1 2024, worth a combined $126M — up 1,000% from $11.4M a quarter earlier.
Sellers outnumbered buyers: 30 funds closed out of QTTB and 13 opened new positions — a net loss of 17 holders — while 14 trimmed existing stakes and 5 added.
The largest buyer was OrbiMed, opening a new position worth an estimated $31M. The largest seller was Newtyn Management, exiting entirely with an estimated $851K sold.
- 39 institutional investors held Q32 Bio (QTTB) as of Q1 2024, down from 57 in Q4 2023.
- Funds reported $126M of Q32 Bio stock for Q1 2024, up 1,000% quarter-over-quarter.
- 13 funds opened new Q32 Bio positions in Q1 2024 and 30 closed out, a net change of -17 holders.
- The largest Q32 Bio buyer in Q1 2024 was OrbiMed, an estimated $31M added.
- The largest Q32 Bio seller in Q1 2024 was Newtyn Management, an estimated $851K sold.
Based on aggregated 13F filings for Q1 2024.